[ad_1] <br><img src="https://images.wsj.net/im-09554860/medium" /><br>Eli Lilly lower its outlook for fourth-quarter income citing sluggish progress out there for incretin, which will increase insulin ranges. <br>[ad_2] <br><a href="https://www.wsj.com/articles/eli-lilly-cuts-sales-outlook-after-sluggish-growth-for-incretin-drugs-fddc3b4e?mod=pls_whats_news_us_business_f">Source link </a>